| Name | Title | Contact Details |
|---|---|---|
Aubrey Haddach |
General Counsel and Corporate Secretary | Profile |
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.
ABR--Affinity BioReagents is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Reviva Pharmaceuticals is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Univercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines - for all. Univercells designs innovative production processes to significantly decrease the size of the necessary equipment and facility, for a lower capital and operational cost. The company`s process intensification and integration technology entails smaller footprint and unit cost while offering flexible capabilities, from small to large batches. Deployment of affordable production units enables `in-country, for-country` biologics production, creating value for manufacturers and healthcare systems with cost efficiency and local supply while increasing patients` access to healthcare. Univercells was founded in 2013 by experienced entrepreneurs Hugues Bultot, CEO, and José Castillo, CTO, who bring close to 25 years of expertise in the biotechnology and life sciences sectors. Headquartered in Gosselies (Belgium), Univercells benefits from support from the Walloon region, and received €3 million from Takeda in 2015. Most recently, the company was awarded a $12 million grant from the Bill & Melinda Gates Foundation.
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWounds first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Companys lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWounds pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com